Publication Instructions:

BMT CTN Protocol 1802
- Primary and Ancillary Studies –

The requirements below are for publications and presentations made pursuant to the primary BMT CTN Study 1802.

Acknowledgment Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

"Support for this study was provided by grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Xenikos BV. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH."

The following language should be inserted in the acknowledgements for all BMT CTN Studies that utilize CIBMTR data:

The CIBMTR registry is supported primarily by U24CA76518 from the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases and by contract HHSH234200637015C to the Center for International Blood and Marrow Transplant Research from HRSA/DHHS.

Review Requirements:

For all Publications, Reports, Presentations, Symposiums, etc.

BMT CTN: Abstracts, presentations, and proposed publications relating to data obtained from BMT CTN protocols or to activities of BMT CTN Committees or Protocol Teams are to be submitted to the DCC for review.

Xenikos BV ("Contributor") Requirements:

Review Period. Not less than thirty (30) days prior to the earlier of Publication or submission for Publication of any Manuscript, DCC shall, or shall require the Principal Investigator to, provide Contributor with a copy of the Manuscript for identification of any Contributor Invention, Joint Invention, or Contributor Confidential Information. If the Manuscript is an abstract, presentation, or poster, Contributor will use reasonable efforts to complete its review as promptly as possible, however no more than ten (10) business days after receiving the Manuscript for review. DCC will consider in good faith any comments submitted by Contributor regarding the content thereof, but in no event will DCC, BMT CTN, any Participating Site, or any Study investigator be obligated to incorporate Contributor's

comments into a Manuscript, unless one of the justifications under Section 6.B or 6.C. of the Contributor Agreement applies.

Upon identification of Contributor Confidential Information by Contributor, DCC will, or will require Principal Investigators to, consider in good faith requests to delete any Contributor Confidential Information prior to submitting for Publication.

Further Period. At Contributor's request, NMDP will ensure that DCC will delay Publication or submission for Publication of the Manuscript, as the case may be, for sixty (60) days from the date that the Manuscript is provided to Contributor to allow patent applications to be filed, to the extent Contributor is allowed to seek patent protection pursuant to Section 5.B. of the Contributor Agreement, or one or more Inventions not previously Published that are disclosed in the Manuscript. Contributor shall also have the right not to file patent applications and may request deletion of any content of its contributed intellectual property or Confidential Information in the Manuscript.

For correlative studies utilizing biospecimens obtained from the NHLBI Biologic Specimen Repository (operated by the NMDP) and/or clinical data obtained from the NHLBI Data Repository Information Coordinating Center, include the following as applicable:

If the Research Plan involves collaboration with Study Investigators, acknowledge the source of the data by including language similar to the following either in the acknowledgement or in the text of the manuscript:

"This manuscript was prepared using BMT CTN 1802 Research Materials obtained from the NHLBI."

If the Research Plan does not involve collaboration with Study investigators, or if the Study has ended, use the following language:

"This manuscript was prepared using BMT CTN 1802 Research Materials obtained from the NHLBI Biologic Specimen Repository (Operated by the NMDP) and NHLBI Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the BMT CTN 1802 or the NHLBI."

Manuscripts and abstracts resulting from the Research Plan should not use the name of the Study in the title of the manuscript/abstract unless the title clearly denotes the source of the Research Materials as being from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center.

Questions regarding the above requirements may be directed to the Data Coordinating Center, NMDP Contracts & Procurement Department at NMDP_BMTCTN_Pub@nmdp.org.